Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder

OBJECTIVE: Our aim was to determine whether serum C-X-C motif chemokine 5 (CXCL5) may serve as a diagnostic biomarker for relapsing-remitting multiple sclerosis (RRMS) as well as a marker that can be used to predict treatment response. METHODS: CXCL5 levels were measured by ELISA in sera of 20 RRMS...

Descripción completa

Detalles Bibliográficos
Autores principales: Karaaslan, Zerrin, Yilmaz, Vuslat, Yuceer, Hande, Sanli, Elif, Akcay, Halil Ibrahim, Kurtuncu, Murat, Turkoglu, Recai, Tuzun, Erdem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kare Publishing 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331241/
https://www.ncbi.nlm.nih.gov/pubmed/37435281
http://dx.doi.org/10.14744/nci.2022.77861
_version_ 1785070219310399488
author Karaaslan, Zerrin
Yilmaz, Vuslat
Yuceer, Hande
Sanli, Elif
Akcay, Halil Ibrahim
Kurtuncu, Murat
Turkoglu, Recai
Tuzun, Erdem
author_facet Karaaslan, Zerrin
Yilmaz, Vuslat
Yuceer, Hande
Sanli, Elif
Akcay, Halil Ibrahim
Kurtuncu, Murat
Turkoglu, Recai
Tuzun, Erdem
author_sort Karaaslan, Zerrin
collection PubMed
description OBJECTIVE: Our aim was to determine whether serum C-X-C motif chemokine 5 (CXCL5) may serve as a diagnostic biomarker for relapsing-remitting multiple sclerosis (RRMS) as well as a marker that can be used to predict treatment response. METHODS: CXCL5 levels were measured by ELISA in sera of 20 RRMS patients under fingolimod treatment, 10 neuromyelitis optica spectrum disorder (NMOSD) patients, 15 RRMS patients presenting predominantly with spinal cord and optic nerve attacks (MS-SCON), and 14 healthy controls. RESULTS: Fingolimod treatment significantly reduced CXCL5 levels. CXCL5 levels were comparable among NMOSD and MS-SCON patients. CONCLUSION: Fingolimod might regulate the innate immune system. Serum CXCL5 measurement does not differentiate between RRMS and NMOSD.
format Online
Article
Text
id pubmed-10331241
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Kare Publishing
record_format MEDLINE/PubMed
spelling pubmed-103312412023-07-11 Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder Karaaslan, Zerrin Yilmaz, Vuslat Yuceer, Hande Sanli, Elif Akcay, Halil Ibrahim Kurtuncu, Murat Turkoglu, Recai Tuzun, Erdem North Clin Istanb Original Article OBJECTIVE: Our aim was to determine whether serum C-X-C motif chemokine 5 (CXCL5) may serve as a diagnostic biomarker for relapsing-remitting multiple sclerosis (RRMS) as well as a marker that can be used to predict treatment response. METHODS: CXCL5 levels were measured by ELISA in sera of 20 RRMS patients under fingolimod treatment, 10 neuromyelitis optica spectrum disorder (NMOSD) patients, 15 RRMS patients presenting predominantly with spinal cord and optic nerve attacks (MS-SCON), and 14 healthy controls. RESULTS: Fingolimod treatment significantly reduced CXCL5 levels. CXCL5 levels were comparable among NMOSD and MS-SCON patients. CONCLUSION: Fingolimod might regulate the innate immune system. Serum CXCL5 measurement does not differentiate between RRMS and NMOSD. Kare Publishing 2023-06-19 /pmc/articles/PMC10331241/ /pubmed/37435281 http://dx.doi.org/10.14744/nci.2022.77861 Text en © Copyright 2023 by Istanbul Provincial Directorate of Health https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Original Article
Karaaslan, Zerrin
Yilmaz, Vuslat
Yuceer, Hande
Sanli, Elif
Akcay, Halil Ibrahim
Kurtuncu, Murat
Turkoglu, Recai
Tuzun, Erdem
Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder
title Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder
title_full Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder
title_fullStr Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder
title_full_unstemmed Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder
title_short Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder
title_sort serum cxcl5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331241/
https://www.ncbi.nlm.nih.gov/pubmed/37435281
http://dx.doi.org/10.14744/nci.2022.77861
work_keys_str_mv AT karaaslanzerrin serumcxcl5asabiomarkerinmultiplesclerosisandneuromyelitisopticaspectrumdisorder
AT yilmazvuslat serumcxcl5asabiomarkerinmultiplesclerosisandneuromyelitisopticaspectrumdisorder
AT yuceerhande serumcxcl5asabiomarkerinmultiplesclerosisandneuromyelitisopticaspectrumdisorder
AT sanlielif serumcxcl5asabiomarkerinmultiplesclerosisandneuromyelitisopticaspectrumdisorder
AT akcayhalilibrahim serumcxcl5asabiomarkerinmultiplesclerosisandneuromyelitisopticaspectrumdisorder
AT kurtuncumurat serumcxcl5asabiomarkerinmultiplesclerosisandneuromyelitisopticaspectrumdisorder
AT turkoglurecai serumcxcl5asabiomarkerinmultiplesclerosisandneuromyelitisopticaspectrumdisorder
AT tuzunerdem serumcxcl5asabiomarkerinmultiplesclerosisandneuromyelitisopticaspectrumdisorder

Ejemplares similares